Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
The Miriam Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00887653CT.gov Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hypertriglyceridemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Raltegravir (this asset) | The Miriam Hospital | P3 | BB · 64 |
| Fenofibrate | Abbott | P4 | BB |
| Saffron | Birjand University of Medical Sciences | P4 | BB |
| (3S)-TETRAHYDRO-3-FURYL ((.ALPHA.S)-.ALPHA.-((1R)-1-HYDROXY-2-(N1-ISOBUTYLSULFANILAMIDO)ETHYL)PHENETHYL)CARBAMATE PHOSPHATE (ESTER) | Felizarta, Franco, M.D. | P4 | BB |
| Atorvastatin | The University of Western Australia | P4 | BB |
| NORVIR | Felizarta, Franco, M.D. | P4 | BB |
| Simvastatin | Koval' O., MD | P4 | BB |
| Niacin | University of South Dakota | P4 | B |
| Telmisartan | Ludwig-Maximilians - University of Munich | P3 | B |
+19 more in the Hypertriglyceridemia cohort
Other indications for Raltegravir
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| HIV Infectious Disease | — | P4 | A · 80 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P4 | BB · 68 |
| Osteoporosis | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FenofibrateAbbottBB
- SaffronBirjand University of Medical SciencesBB
- (3S)-TETRAHYDRO-3-FURYL ((.ALPHA.S)-.ALPHA.-((1R)-1-HYDROXY-2-(N1-ISOBUTYLSULFANILAMIDO)ETHYL)PHENETHYL)CARBAMATE PHOSPHATE (ESTER)Felizarta, Franco, M.D.BB
- AtorvastatinThe University of Western AustraliaBB
- NORVIRFelizarta, Franco, M.D.BB
Citation
Floatz Terminal. Raltegravir in Hypertriglyceridemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/raltegravir-hypertriglyceridemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →